women who used menopausal hormone therapy compared with women who never used it ( 5 -7 ).
In July 2002, the Women ' s Health Initiative (WHI) estrogenplus-progestin trial, a randomized, double-blinded, placebocontrolled clinical trial of estrogen-plus-progestin use among postmenopausal women for primary prevention of chronic disease was stopped early because risks exceeded benefi ts ( 7 ) . Increased risks of breast cancer among the women assigned to take estrogen plus progestin contributed specifi cally to the conclusion that overall health risks exceeded benefi ts of use of estrogen plus progestin in the WHI. After the release of these WHI fi ndings, menopausal hormone therapy use by American women substantially declined in 2003 ( 8 ) . Recently released data from the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) program showed a marked, statistically signifi cant decline in breast cancer incidence in 2003 and 2004, after showing smaller and non -statistically signifi cant declines starting in 1999 ( 9 ) . This fi nding sparked speculation that the widespread cessation of menopausal hormone therapy use after the WHI was responsible for the drop in breast cancer incidence because fewer women taking menopausal hormone therapy would mean fewer women exposed to the increased breast cancer risk that accompanies use of estrogen plus progestin ( 10 ) .
Between 2000 and 2005, nationwide use of screening mammography fell by 4% overall among women aged 40 years or older and by almost 7% among women aged 50 -64 years ( 11 ) . Despite strong circumstantial evidence for a link between recent changes in menopausal hormone therapy use and lower nationwide breast cancer incidence, the recent changes in mammography use and the absence of data from single, defi ned populations in which one could directly evaluate all three factors -breast cancer incidence, menopausal hormone therapy use, and mammography -have raised questions about the determinants of the recent decline in US breast cancer incidence rates. To address these questions, we assessed data on breast cancer incidence, dispensed menopausal hormone therapy prescriptions, and screening mammography at KPNW, a large, prepaid health plan. Incorporating data through December 31, 2006 , also permits an assessment of more recent patterns than are available in the NCI SEER program.
Subjects and Methods

Data Source
Our study population comprised female KPNW members who participated in the plan from January 1, 1980, to December 31, 2006 . Members receive essentially all preventive and therapeutic care from KPNW physicians at KPNW-owned hospitals or at leased beds in local facilities. Virtually all cancer care occurs within these KPNW facilities under the direction of KPNW physicians. The racial/ethnic distribution of KPNW members (approximately 82% white, 3% African American, 5% Asian American, 5% Hispanic, and 5% other) ( 12 ) reflects that of the surrounding Portland, OR, metropolitan area and has not substantially changed during the study period. Since 1982, KPNW has included Medicare enrollees. Medicare members account for 13% -15% of the KPNW population, are fully integrated into the health plan, and receive care that is identical to that received by non-Medicare members of KPNW.
The inclusion of Medicare patients has increased the percentage of older women in KPNW. Since 1986, women aged 45 -59 years old and women aged 60 years or older have constituted 25% and 20%, respectively, of the KPNW female population, which reached 255 171 on June 30, 2006 . Approximately 15% of members leave the KPNW plan each year, but the actual number of plan members has increased every year for nearly 60 years. Almost all non-Medicare KPNW members receive employer-based health insurance.
The KPNW system includes computerized administrative, clinical, mammography, and pharmacy databases that allow linkage of several sources of data for all members of the plan. KPNW also maintains a tumor registry that has been fully integrated into these data systems since 1970. Repeated audits in conjunction with continuing accreditation surveys every 3 years by the Commission on Cancer of the American College of Surgeons have verifi ed 95% -98% ascertainment of all newly diagnosed cancers among KPNW members.
Using the KPNW tumor registry fi les, we identifi ed all incident primary invasive breast cancers that were diagnosed among KPNW plan members between January 1, 1980, and December 31, 2006. All cases are routinely coded from the pathology reports according to the current edition of the International Classifi cation of Diseases for Oncology (ICD-O).
CONTEXT AND CAVEATS
Prior knowledge
The incidence of breast cancer in the United States has risen steadily in recent decades through 2003, when incidence began to decline. Rates of menopausal hormone therapy use and screening mammography have also changed over time, and the relative contributions of these factors to the incidence of breast cancer is unclear.
Study design
Analysis of time trends in breast cancer incidence, dispensed menopausal hormone therapy prescriptions, and screening mammography use among women enrolled in a large health plan from 1980 through 2006. 
Contribution
Implications
The rise in breast cancer incidence rates through the late 1990s is consistent with the effects of mammography screening and increasing use of menopausal hormone therapy, and the recent decline in incidence is consistent with the drop in hormone use.
Limitations
This descriptive, population-level study examined aggregate data, so changes in other unmeasured risk factors could theoretically explain the observed incidence patterns.
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Pathology
The KPNW Department of Pathology reviews pathology specimens from all newly diagnosed cancers, including those from the approximately 15% of KPNW members who are initially diagnosed at community hospitals. The Department works largely in a single central location with frequent consultations, collaborative quality reviews, and requisite quality assurance activities.
Hormone Receptor Status
Tumor specimens from KPNW patients have been analyzed for estrogen receptor (ER) status since the mid-1970s. Assays were performed at the Oregon Health and Science University from 1980 through 1990, at Nichols Laboratory from 1991 through 1997, and at the KPNW Laboratory since 1998. All laboratories passed quality reviews of the NCI-sponsored clinical cooperative groups for accuracy and quality of receptor measurement. The reagents for, methods of staining of, and analysis and definitions of positive and negative reporting of immunohistochemistry-based ER status by KPNW pathologists have not changed since 1998. The percent of tumors analyzed for ER status increased from 67% in 1980 to 81% in 1989, 89% in 1994, and 99% in 2006.
Mammography Rates
The computerized Radiology Information Management system (RIM) at KPNW records every radiologic procedure among KPNW members. Mammograms at KPNW are coded as either "screening" or "diagnostic." During the entire study period (1980 -2006) , KPNW general radiology benefits have covered all mammograms at KPNW facilities. Mammograms at other facilities are neither covered nor reimbursed, so RIM captures essentially all mammograms received by KPNW members. We used population figures from KPNW administrative files to calculate annual percentages of female KPNW members who received screening mammography between 1980 and 2006. We calculated annual agespecific proportions (for women aged 45 -59 years and ≥ 60 years) of KPNW members who received screening mammography by dividing the total number of screening mammograms performed at KPNW each year by the total number of women in that age group in KPNW. For 1992 -2006, we also obtained KPNW-computed rates for the percent of women receiving a mammogram at least once every 2 years; such data are required of health plans reporting in the Health Plan Employer Data and Information Set.
Pharmacy Data
Kaiser Permanente operates a large in-and outpatient pharmacy system that serves KPNW members throughout the region. More than 70% of KPNW members had pharmacy benefits after 1987, and 93% -97% of members had them after 1993. Members who fill prescriptions at non-KPNW pharmacies must pay full price for medications, which means that essentially all prescriptions were filled at KPNW.
Since 1987, The Outpatient Pharmacy System (TOPS) at KPNW has tracked all medications obtained by KPNW members by recording each drug and dose dispensed. We queried TOPS for the numbers of prescriptions dispensed by KPNW pharmacies between 1988 and 2006. We used the number of oral estrogen or oral estrogen-plus-progestin prescriptions dispensed by KPNW pharmacies to calculate annual age-specifi c proportions of KPNW members who received at least one estrogen or estrogen-plusprogestin prescription. Members who fi lled multiple prescriptions for these medications during the year were counted only once for each particular medication.
Until 2005, almost all estrogens dispensed at KPNW pharmacies were oral conjugated equine estrogens, with only a small percentage of women receiving prescriptions for oral micronized estradiol. Starting in 2005, estradiol replaced conjugated equine estrogens as the predominant oral estrogen dispensed at KPNW pharmacies. Estrogen plus progestin was prescribed as two separate prescriptions, one for these oral estrogens and one for oral medroxyprogesterone acetate (MPA). KPNW physicians have only rarely prescribed unopposed MPA or the single tablet that contains both estrogen and MPA. Therefore, the number of dispensed oral "progestins" accurately estimates the number of dispensed estrogen-plus-progestin prescriptions. We estimated the number of dispensed prescriptions for unopposed estrogen by subtracting the number of dispensed progestins from the number of dispensed estrogens.
Statistical Analysis
Health plan membership counts provided the population figures for calculating incidence rates. Both age-specific and age-adjusted incidence rates of invasive breast cancer were calculated, with the adjusted rates standardized by the direct method to the US 2000 standard population ( 13 ) . Rates are expressed per 100 000 women per year and presented as 2-year moving averages to reduce random variation. All figures are displayed according to the recommendations of Devesa et al. ( 14 ) .
We assessed temporal changes in incidence rates via joinpoint regression ( 15 ), a method of weighted least squares log-linear regression analysis that uses joined straight-line segments to identify time points at which statistically signifi cant changes in incidence rates occur ( 16 ) . For trends in breast cancer incidence rates by age group and ER status, we fi t joinpoint regression models with up to three joinpoints (i.e., up to four straight-line segments) and chose the best-fi tting model based on permutation tests that were adjusted for multiple comparisons to maintain an overall twosided P value of less than .05. After the number of joinpoints was identifi ed, each joined line segment was expressed as an annual percentage change (APC) with a corresponding 95% confi dence interval (CI). We used the 2-year moving average incidence rates to identify the best-fi tting model (i.e., to identify the time points at which statistically signifi cant changes in breast cancer incidence occurred) and to calculate the APCs. The joinpoint regression analysis confi rmed these patterns and identifi ed three years at which statistically signifi cant changes in breast cancer incidence rate trends occurred: 1983, 1986, and 2001. When expressed as APCs, incidence rates fell 1.8% per year (95% CI = -8.6% to 5.6%) from 1980 to 1983, increased 10.6% per year (95% CI = 4.2% to 27.9%) from 1983 to 1986, increased 0.7% per year (95% CI = 0.01% to 1.4%) from 1986 to 2001, and then declined 4.3% per year (95% CI = -7.2% to -1.1%) from 2001 to 2006.
Results
Breast Cancer Incidence at Kaiser Permanente Northwest
Age-Specific Incidence Rates
For women younger than 45 years of age, there was essentially no change in incidence rates of invasive breast cancer over the 27-year period (Fig. 1) . Incidence rates increased both among women aged 45 -59 years and women aged 60 years and older. From the early 1980s to 1992 -1993, incidence rates increased more rapidly among 
Stage-Specific Incidence Rates
Increasing rates of cancers diagnosed at localized stagesessentially node-negative cancers confined to the breast -accounted for almost all the overall rate increase from 1980 through 1998 -1999 (Fig. 2) 
Estrogen Receptor Status
There were dramatic differences in the incidence rate trends by ER status ( Fig. 3 ) .
The three joinpoints (1983, 1986 , and 2001) for statistically signifi cant changes in ER+ incidence rate trends were the same as those for overall breast cancer incidence rate trends. Expressed as APCs, these four trends refl ected a 5.0% (95% CI = 3.7% to 14.4%) annual increase from 1980 to 1983, a 18.9% (95% CI = 0.1% to 41.2%) annual increase from 1983 to 1986, a 2.1% (95% CI = 1.2% to 2.9%) annual increase from 1986 to 2001, and a 2.7% (95% CI = -6.4% to 1.1%) annual decrease from 2001 to 2006.
In contrast to the incidence rates trends for the ER+ tumors, those for ER-negative (ER − ) tumors, which were based on fewer cases and were somewhat more variable, showed no evidence of an increase over the entire 27-year period. Instead, incidence rates fl uctuated but declined overall throughout the 1980s and then remained level throughout much of the 1990s until an abrupt decline after 1999. This latter decline showed no evidence of abating, dropping steadily from 24.0 per 100 000 women in 2002 -2003 to 15.9 per 100 000 in 2004 -2005 and 16.6 per 100 000 in 2005 -2006 . The APCs for ER -incidence rates were -2.1% (95% CI = -3.2% to -1.0%) from 1980 to 1995, 3.7% (95% CI = -9.0% to 18.1%) from 1995 to 1999, and -9.8% (95% CI = -12.8% to -6.6%) from 1999 to 2006.
Mammography
Screening mammography was not common at KPNW before 1982; less than 5% of women aged 45 years or older underwent the procedure each year ( Fig. 4 ) . Beginning in 1983, the proportion of women receiving annual mammography rose rapidly to approximately 25% in 1986. After a brief plateau in 1986 -1987, the proportion rose to 48.1% (95% CI = 47.6% to 48.7%) in 1991 among women aged 45 -59 years and 46.0% (95% CI = 45.5% to 46.5%) in 1998 among women aged 60 years or older. Neither tamoxifen nor raloxifene was widely dispensed at KPNW during the study period. In women aged 45 -59 years, tamoxifen dispensings increased from 0.1% in 1988 to 0.9% in 1994 and then remained stable at 0.8% -1.1% through 2006. In women aged 60 years or older, dispensing rose from 0.5% in 1988 to 1.9% in 1992 and then remained stable (1.8% -2.3%) through 2006. Between 1998 and 2006, raloxifene was dispensed to 0.06% -0.21% of women aged 45 -59 years and 0.09% -0.41% of women aged 60 years or older.
Discussion
We previously described ( 1 ) a steady rise in breast cancer incidence rates among older women enrolled in KPNW from the early 1960s to early 1980s, which seemed, at least in the later years, to be restricted to ER+ tumors ( 2 ). In our update and expansion of these data, we observed three major patterns. First, breast cancer incidence rates rose markedly -by 28% overall -from 1982 -1983 (when rates were 103.2 per 100 000) to 1992 -1993 (131.7). Second, after slightly declining, the rates then rose steadily but more slowly - by 15% overall -through 2000 -2001 (151.3) . Finally, the rates dropped dramatically -by 18% -through 2004 and then leveled off through 2006 (126.2). Rates as low as these were last observed in the mid-1980s.
The rise in incidence rates throughout the 1980s and early 1990s is qualitatively and quantitatively consistent with the simultaneous adoption of screening mammography at KPNW. The proportion of women regularly screened progressively rose from a few percent in 1980 to 75% after 1993. In general, populations into which screening mammography is introduced demonstrate increased breast cancer incidence rates from three sources. Initially, women undergoing their fi rst screen experience a major increase in rate due to the detection of prevalent, small, slowgrowing tumors that have accumulated over several years. This "prevalence" rate, in the fi rst year of screening, is generally 50% -100% higher than that seen in unscreened populations ( 17 , 18 ) .
The incidence rates in screened populations decline following the initial screening but plateau at rates higher than those in unscreened populations because of two other sources of increase. First, as a result of the lead time introduced by screening, age at diagnosis declines, on average, by 2 -4 years. Second, some tumors that might never have come to clinical recognition without mammography -particularly small, slower-growing tumors -are detected (i.e., "overdiagnosis" or length -time bias). Although the presence of these two sources of increased breast cancer incidence in screened populations is generally accepted, their quantitative effect on breast cancer incidence rates is controversial; estimates range from a 10% to a 50% excess compared with incidence in unscreened populations (18, 19) .
We believe that the rapid rise in breast cancer rates up to the early 1990s seen in the KPNW refl ects these three sources of increase, with the slight decline at that point marking the exhaustion of large numbers of previously unscreened women undergoing prevalence examinations. The new baseline rate, which is approximately 30% higher than the baseline rate seen before screening began in the early 1980s, is consistent with, albeit at the higher end of, the estimates for the excess expected due to lead time and overdiagnosis in screened women (i.e., a 30% overall increase translates to a 40% increase in the 75% of the population being screened).
Not only is the total rise in incidence rates that we observed in KPNW women through the early 1990s consistent with screening effects, but the characteristics of the rise are as well. Rapidly rising rates from the early 1980s (103. 2 in 1982 -1983) through 1987 (146.3 in 1986 -1987) closely correspond to the concurrent sharp initial increase in mammography screening. The subsequent temporary plateauing of screening rates occurred at the same time as the pause in increase in annual mammography screening, and the subsequent rise in cancer rates, albeit at a lower pace than the initial rise, mimicked the fi nal twofold rise in mammography. The greater rise in breast cancer incidence rates among women aged 60 years or older than women aged 45 -59 years is also consistent with screening effects: older women have had more years to both accumulate prevalent tumors and have detected tumors that, in the absence of screening, would have been undetected before they died of other causes. Other factors, such as increasing menopausal hormone therapy use, may have contributed to the rise in rates during the 1980s, particularly because the total increase is at the upper end of what might be expected from mammography alone. However, the substantial infl uence of screening complicates attempts to quantify effects of other factors. By the early 1990s, the percentage of the population receiving screening mammograms leveled off, which essentially rules out mammography as an explanation for the second rise in incidence (from 132. ( 8 , 20 , 21 ) and are likely related to reports from two clinical trials [the Heart and Estrogen/progestin Replacement Study in 2000 ( 22 ) and WHI estrogen-plus-progestin results in 2002 ( 7 )] that documented harm associated with use of menopausal hormone therapy for chronic disease prevention. Increased cessation of estrogen-plus-progestin use would be expected to produce immediate effects on breast cancer incidence because the increased breast cancer risk associated with estrogen plus progestin is a late-stage effect: breast cancer risk is higher in current users but rapidly declines after cessation of use ( 5 ) and returns to the level in non users within 5 years. The larger rate increase in the 1990s in the younger versus older women is also consistent with the more frequent use of estrogen plus progestin by younger women and with the higher risks associated with this formulation versus unopposed estrogen ( 6 ).
Our The incidence trends by receptor status are provocative. The patterns for ER+ cancers will resemble those for total breast cancer because ER+ cancers currently make up more than 80% of breast cancers diagnosed in women older than 45 years of age. It is also consistent with the likelihood that they contribute disproportionately to the slow-growing tumors that are detected with the introduction of mammography, and their stronger association with menopausal hormone therapy use in studies that fi nd a difference by receptor status ( 24 ) . The incidence rates of ER+ cancer fell sharply from 122. that some ER+ tumors in menopausal hormone therapy users were undetected yet invasive, such that cessation of menopausal hormone therapy may have simply retarded their growth and postponed their diagnosis by 1 or 2 years. Alternatively, as noted, the KPNW pharmacy shifted estrogen prescriptions from primarily conjugated equine estrogen to estradiol formulations in 2005. Elevated breast cancer risk has been found with both types of estrogens, but potential risk differences have been the source of unconfi rmed ( 25 ) speculation ( 26 ) .
The patterns for ER -tumors are more enigmatic. Their rate did not rise during the period of rapid increase in mammography screening, and indeed substantially declined between 1999 and 2006. We anticipated that screening effects would be more apparent for ER+ tumors, which make up a higher percentage of screening-detected cancers than of interval cancers ( 27 , 28 ) . However, we also expected to see some screening effects on ER − incidence rates. The lack of any rise in incidence of ER − tumors during the 1990s (when menopausal hormone therapy use substantially increased), followed by a decline in incidence over 2003 -2006 that was even more precipitous than the decline seen for ER+ tumors, is particularly diffi cult to interpret. ER − cancers are far less common than ER+ cancers at KPNW, and thus, instability in the rate estimates could have obscured patterns. There were no identifi able changes in laboratory procedures at KPNW that would have alone accounted for the increased incidence of ER+ tumors and decreased incidence of ER − tumors, but temporal changes in other unknown risk factors for ER − tumors ( 29 ) would limit our ability to evaluate the potential association between mammography screening, menopausal hormone therapy use, and incidence of ER − tumors. Simple shifts from ER-unknown to ER+ or ER − cannot explain the increased incidence of ER+ tumors; between 2000 and 2006, as incidence of both ER+ tumors and ER − tumors declined, the percentage of breast cancers with unknown ER status fell from 4% to less than 1%.
Our study has limitations. Similar to other investigations of the impact of mammography and menopausal hormone therapy on breast cancer incidence rates ( 30 , 31 ) , ours is a descriptive study evaluating whether population-based rates, rather than individuallevel data, were associated with aggregate measures of mammography screening and menopausal hormone therapy prescribing patterns. Thus, it is possible that changes in other, unmeasured causes could have produced the incidence patterns that we observed. However, credible evidence of dramatic changes in other breast cancer risk factors after 2000 has not been documented. We also analyzed data on dispensed hormone therapy prescriptions. To the extent that women did not comply with the prescriptions, we will have underestimated actual usage. On the other hand, by relying on pharmacy dispensing records, we eliminated errors associated with patient recall and reporting. In the aggregate, potential biases due to misclassifi ed hormone therapy use or mammography screening are likely to be small and nondifferential. Other publications hypothesized that lower breast cancer incidence rates nationwide in 2003 and 2004 were correlated with decreased menopausal hormone therapy use in other populations after 2002 ( 10 , 32 ) . Our data from the KPNW health plan, where breast cancer incidence rates are almost identical to incidence rates in NCI SEER, show that, in a single, large, study at Pennsylvania State University on April 26, 2014 http://jnci.oxfordjournals.org/ Downloaded from population, the statistically signifi cant decline in breast cancer incidence rates continued through December 31, 2006 . Using hormone therapy dispensing data and mammography screening statistics in the KPNW health plan, we showed that breast cancer incidence rates and hormone therapy prescriptions followed par- In summary, since 1980, time trends in breast cancer incidence, particularly for ER+ tumors, seem consistent with the impact of major changes in patterns of mammography screening and use of menopausal hormone therapy. While incidence rates for women under age 45 years remained stable, the rates for women aged 45 -59 years and women aged 60 years or older both rose about 50% from the early 1980s to 2001. This rise seemed to occur in two phases, the fi rst during the 1980s, coinciding with the progressive adoption of screening mammography by 75% -79% of eligible women in the plan, and the second corresponding to increases in menopausal hormone therapy use, particularly combined therapy, throughout the 1990s. The incidence rates for both older age groups dropped dramatically in 2003 -2006 in conjunction with a profound decline in menopausal hormone therapy prescriptions. Whereas ER − tumor incidence showed the recent dramatic decline, it did not show the two earlier rises.
